Analytical Data
-
Gene name
CGAS
- Application
-
Alternative Names
2'3'-cGAMP synthase Mab-21 domain-containing protein 1
-
Species
Human
-
Source
E. coli
-
Tag
N- His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q8N884
-
Expression Region
161-522aa
-
Molecular Weight
48.3 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CGAS (cyclic GMP-AMP synthase) is a crucial enzyme in the innate immune response, playing a significant role in recognizing cytosolic DNA and initiating a signaling cascade that leads to the production of type I interferons. This process is essential for the detection of infections and cellular stress, as well as for maintaining genomic integrity. CGAS is activated upon binding to double-stranded DNA, leading to the synthesis of cyclic GMP-AMP (cGAMP), which acts as a second messenger to activate the STING (stimulator of interferon genes) pathway. Research has shown that dysregulation of CGAS can contribute to various autoimmune diseases and cancer, highlighting its potential as a therapeutic target. The study of recombinant CGAS proteins is critical for understanding its structure-function relationships, elucidating activation mechanisms, and facilitating the development of CGAS-targeted therapies. By producing and characterizing recombinant CGAS, researchers can explore its enzymatic activity, identify regulatory domains, and assess how mutations might affect its function. This research is pivotal for designing novel immunomodulatory drugs and for providing insights into the role of CGAS in health and disease, ultimately paving the way for advanced therapeutic strategies against infections and autoimmune disorders.
